Literature DB >> 24778030

Targeting aurora kinase A inhibits hypoxia-mediated neuroblastoma cell tumorigenesis.

Carmelle V Romain1, Pritha Paul, Sora Lee, Jingbo Qiao, Dai H Chung.   

Abstract

BACKGROUND/AIM: It is unknown whether hypoxia regulates aurora kinase A (AURKA), a serine/threonine kinase, in neuroblastoma to stimulate cell growth or migration. We sought to determine whether AURKA mediates hypoxia-induced regulation of neuroblastoma tumorigenicity.
MATERIALS AND METHODS: Human neuroblastoma BE(2)-C cells were treated with CoCl2, a chemical hypoxia mimetic, and MLN8237, a pharmalogical inhibitor of AURKA, to assess cell viability, colony formation and transwell migration. Focal adhesion kinase (FAK) expression was analyzed after silencing of AURKA under normoxic vs. hypoxic conditions.
RESULTS: Hypoxia up-regulated expression of AURKA mRNA and protein. CoCl2 stimulated cell proliferation and migration, while inhibiting colony formation. MLN8237 reduced colony formation and cell migration. Silencing of AURKA reduced expression of FAK and pFAK under normoxia and hypoxia.
CONCLUSION: Hypoxia positively regulates AURKA expression. Hypoxia-induced stimulation of colony formation and migration is, in part, mediated by AURKA. These findings establish that AURKA is a critical regulator of hypoxia-mediated tumor progression in neuroblastoma.

Entities:  

Keywords:  AURKA; hypoxia; neuroblastoma; tumorigenesis

Mesh:

Substances:

Year:  2014        PMID: 24778030      PMCID: PMC4165572     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  22 in total

Review 1.  New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.

Authors:  Braden D Cox; Meera Natarajan; Michelle R Stettner; Candece L Gladson
Journal:  J Cell Biochem       Date:  2006-09-01       Impact factor: 4.429

2.  Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype.

Authors:  Annika Jögi; Ingrid Øra; Helén Nilsson; Asa Lindeheim; Yuichi Makino; Lorenz Poellinger; Håkan Axelson; Sven Påhlman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 3.  Aurora kinase inhibitors--rising stars in cancer therapeutics?

Authors:  Altaf A Dar; Laura W Goff; Shahana Majid; Jordan Berlin; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

4.  Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.

Authors:  Carmelle Romain; Pritha Paul; Kwang Woon Kim; Sora Lee; Jingbo Qiao; Dai H Chung
Journal:  J Pediatr Surg       Date:  2013-10-05       Impact factor: 2.545

5.  Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1.

Authors:  Alexandra Klein; Daniela Flügel; Thomas Kietzmann
Journal:  Mol Biol Cell       Date:  2008-06-18       Impact factor: 4.138

Review 6.  FAK expression regulation and therapeutic potential.

Authors:  Shufeng Li; Zi-Chun Hua
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

7.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

8.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.

Authors:  T G Graeber; C Osmanian; T Jacks; D E Housman; C J Koch; S W Lowe; A J Giaccia
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

9.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Authors:  Tobias Otto; Sebastian Horn; Markus Brockmann; Ursula Eilers; Lars Schüttrumpf; Nikita Popov; Anna Marie Kenney; Johannes H Schulte; Roderick Beijersbergen; Holger Christiansen; Bernd Berwanger; Martin Eilers
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

10.  Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors.

Authors:  L V Owens; L Xu; R J Craven; G A Dent; T M Weiner; L Kornberg; E T Liu; W G Cance
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

View more
  6 in total

1.  Aurora kinases as targets in drug-resistant neuroblastoma cells.

Authors:  Martin Michaelis; Florian Selt; Florian Rothweiler; Nadine Löschmann; Benedikt Nüsse; Wilhelm G Dirks; Richard Zehner; Jindrich Cinatl
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 2.  The Different Routes to Metastasis via Hypoxia-Regulated Programs.

Authors:  Ana Rita Nobre; David Entenberg; Yarong Wang; John Condeelis; Julio A Aguirre-Ghiso
Journal:  Trends Cell Biol       Date:  2018-07-23       Impact factor: 20.808

3.  Genome-wide association analysis of adaptation to oxygen stress in Nile tilapia (Oreochromis niloticus).

Authors:  Xiaofei Yu; Hendrik-Jan Megens; Samuel Bekele Mengistu; John W M Bastiaansen; Han A Mulder; John A H Benzie; Martien A M Groenen; Hans Komen
Journal:  BMC Genomics       Date:  2021-06-09       Impact factor: 3.969

Review 4.  Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors:  Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

5.  Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.

Authors:  E Hasanov; G Chen; P Chowdhury; J Weldon; Z Ding; E Jonasch; S Sen; C L Walker; R Dere
Journal:  Oncogene       Date:  2017-01-23       Impact factor: 8.756

6.  CEP41-mediated ciliary tubulin glutamylation drives angiogenesis through AURKA-dependent deciliation.

Authors:  Soo Mi Ki; Ji Hyun Kim; So Yeon Won; Shin Ji Oh; In Young Lee; Young-Ki Bae; Ki Wha Chung; Byung-Ok Choi; Boyoun Park; Eui-Ju Choi; Ji Eun Lee
Journal:  EMBO Rep       Date:  2019-12-29       Impact factor: 8.807

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.